Literature DB >> 33252582

WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN THE DIAGNOSIS OF SUSAC SYNDROME.

Monika J Turczyńska1, Przemysław Krajewski1, Joanna E Brydak-Godowska1,2.   

Abstract

PURPOSE: To present the clinical manifestations and results of key diagnostic investigations in patients with Susac syndrome, with special emphasis on the principal role of fluorescein angiography (FA) of the peripheral retina.
METHODS: A retrospective analysis of medical records (collected 2000-2019) of 20 patients (15 women and five men), aged 20 to 51 years (mean age: 31.6 years) with complete or incomplete Susac syndrome diagnosed by an ophthalmic examination and widefield fluorescein angiography (WF-FA) by Spectralis and Optos Tx200.
RESULTS: Fluorescein angiography abnormalities included vascular changes in the posterior pole in 64.7% and in the peripheral retina in 82.4%. Widefield FA abnormalities in the peripheral retina alone were seen in 35.3% and in the posterior pole, but without peripheral vascular involvement, in 17.6%. Secondary leakage from veins was noted in 58.8%.
CONCLUSION: Widefield FA of the peripheral retina has a key role in cases of suspected Susac syndrome as it confirms the diagnosis and assesses disease activity. In addition to the characteristic findings, late-phase FA revealed leakage from veins which is not a typical sign. Patients experiencing migraine headaches may benefit from increasing awareness of neurologists and otologists who more promptly referred patients with suspected Susac syndrome for ophthalmologic evaluation and WF-FA of the peripheral retina.

Entities:  

Mesh:

Year:  2021        PMID: 33252582     DOI: 10.1097/IAE.0000000000003051

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Peripheral arterial filling time and peripheral retina fluorescence features in ultra-widefield angiography.

Authors:  Hai-Cheng She; Xi-Fang Zhang; Yong-Peng Zhang; Xuan Jiao; Hai-Ying Zhou
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.